Morfeo (Zaleplon)

Zaleplon, the active ingredient in Morfeo, is a non‑benzodiazepine hypnotic (Z‑drug) presented as an oral tablet for oral use. It is indicated for the short‑term treatment of sleep onset insomnia in adult patients who have difficulty falling asleep.

GNH USA supplies Morfeo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides reliable sourcing for regulated markets. Our global logistics network ensures timely delivery and compliance with import regulations across continents.

Zaleplon is a non‑benzodiazepine hypnotic used to manage sleep onset insomnia, a disorder characterized by difficulty initiating sleep.

Sleep onset insomnia: reduces sleep latency and helps patients fall asleep more quickly during short‑term therapy. Transient insomnia due to stress: improves ability to initiate sleep in acute stress‑related episodes. Acute insomnia after shift work: facilitates quicker sleep onset for individuals with temporary sleep disruption.

Common Side Effects: - Dizziness - Headache - Nausea - Taste disturbance - Transient somnolence - Amnesia

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, anaphylaxis) - Complex sleep behaviors (sleep‑walking, sleep‑driving) - Depression or suicidal thoughts - Respiratory depression when combined with other CNS depressants - Hallucinations or psychomotor agitation

Before initiating therapy, evaluate the patient’s sleep disorder and medical history. - Concomitant CNS depressants: avoid or use with caution to prevent excessive sedation. - Hepatic impairment: adjust therapy as metabolism may be reduced. - Dependence risk: limit use to the shortest duration necessary. - Abrupt discontinuation: taper if therapy exceeds recommended period. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Zaleplon may interact with several drug classes that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Other hypnotics, benzodiazepines, opioids, or alcohol: may cause profound sedation and respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase plasma concentrations and risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels. - Certain antidepressants (e.g., fluoxetine, sertraline): may enhance sedative effects. - Antihistamines: can add to drowsiness and impair alertness.